A 2026 review concluded that GLP-1 receptor agonists have plausible stroke biology and modest prevention signals, but current human evidence does not support routine use as acute ischemic stroke neuroprotection.1 The useful clinical split is prevention in cardiometabolic patients vs. acute brain-rescue treatment after stroke onset. Research Highlights Acute neuroprotection is not established: the 2026 …
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) act on the brain as well as the gut, and a 2026 real-world cohort study from Kamel-Abusalha et al. propensity-matched 118,993 GLP-1 RA users to 118,993 non-users in the TriNetX network and found a modest but statistically robust 21–23% higher hazard of new-onset hypersomnolence at 1 and 5 years.1 …
A 2026 meta-analysis of 4 randomized trials found that GLP-1 receptor agonists reduced obstructive sleep apnea severity by 13.89 apnea-hypopnea events per hour compared with placebo, alongside 12.46 kg more weight loss than placebo.1 The effect looks clinically meaningful for obesity-linked sleep apnea, but high heterogeneity means the result should not be flattened into “GLP-1 …